Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,811 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06190275Recruiting
Immune cell therapy for advanced head and neck cancer
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06203574Recruiting
TROP-2 PET/CT Scan for Colorectal Cancer Diagnosis
This study tests a new PET/CT scan that uses a special tracer (TROP-2) to take pictures of solid tumors, like colorectal cancer. The goal is to see if this scan can help doctors find and diagnose cancer more accurately.
ShanghaiAges 18–65 - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06224387RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug, CTS2190, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if the drug is safe and effective.
Luoyang, HenanAges 18 years+ - NCT06227468Recruiting
Mapping immune system genes in Greek adults
This study maps immune system genes (HLA) in Greek adults. It uses a simple cheek swab sample to collect data, with no experimental treatment.
Chaïdári, AtticaAges 18 years+ - NCT06232083RecruitingPhase 1
Study of Caronizumab with low-dose radiation for certain cancers
This trial tests a combination of an immunotherapy drug (Caronizumab) and a special type of low-dose radiation (PLDR) for people with esophageal, lung, or cervical cancer that has come back or spread after initial treatment. It aims to see if the combination can help stop the cancer from growing.
Hefei, British ColumbiaAges 18–75 - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06233838Recruiting
Hemoperfusion study for kidney patients on dialysis
This trial tests a special blood-filtering treatment (hemoperfusion) for people with advanced kidney disease on regular dialysis. It aims to remove harmful substances that standard dialysis may not fully clear.
Fuzhou, FujianAges 18 years+ - NCT06235931Recruiting
Darcilil with AI and pyrrotinib for advanced breast cancer
This trial tests a combination of three drugs (darcilil, an aromatase inhibitor, and pyrrotinib) for older adults with a specific type of advanced breast cancer that has both HER2 and hormone receptors. It aims to see if this mix works better than current treatments.
Suzhou, JiangsuAges 65 years+ - NCT06251115Recruiting
Study of QY-1-T for advanced HBV-related liver cancer
This study tests a new treatment called QY-1-T for people with advanced liver cancer related to hepatitis B. It is for patients who have already tried other standard treatments and have a certain genetic marker (HLA-A*11:01).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT06263998RecruitingPhase 1
Safety study of NCP112 eye drops in healthy adults
This study tests a new eye drop called NCP112 for safety and how well people tolerate it. Healthy volunteers receive the eye drops and are monitored for any side effects.
Seoul, Daehak-ro, Jongno-guAges 19–50 - NCT06263959RecruitingPhase 2
Testing a new hepatitis B pill (GST-HG131) for chronic HBV
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
BeijingAges 35–65 - NCT06267105Recruiting
Comparing skin incisions for trigger finger surgery
This study compares two different ways of making the skin cut (incision) during surgery for trigger finger. The goal is to see which incision leads to better hand function after recovery.
Sabadell, BarcelonaAges 18–100 - NCT06267183RecruitingEarly Phase 1
Safety study of a new drug in healthy volunteers
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
ShanghaiAges 18–45 - NCT06290011Recruiting
Mixed reality for chronic pain relief
This study tests a new therapy that uses mixed reality (a type of glasses that shows virtual images over the real world) to help distract you from pain and teach relaxation. It may help people with chronic pain who have not tried VR or MR before.
Shanghai, YangpuAges 18–85 - NCT06296706RecruitingPhase 3
Study of a new docetaxel for advanced stomach cancer
This trial is testing a new form of the chemotherapy drug docetaxel (called albumin-bound docetaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this version of the drug works better or has fewer side effects.
Shijiazhuang, HebeiAges 18–75 - NCT06307080Recruiting
Combined ablation and immunotherapy for pancreatic cancer with liver spread
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06311968RecruitingPhase 2
Proton radiation after surgery for thymus tumors
This trial tests a type of precise radiation called proton therapy after surgery for thymus tumors. It may help reduce the chance of the tumor coming back while limiting side effects to nearby organs.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06311955RecruitingPhase 2
Carbon ion radiation for residual thymus tumor after surgery
This trial tests a type of radiation called carbon ion therapy for people with thymus cancer that was not completely removed during surgery. The goal is to see if this treatment can target the remaining tumor cells safely and effectively.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,811 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.